Dopaminergic neuronal loss in transgenic mice expressing the Parkinson's disease-associated UCH-L1 I93M mutant

Neurochemistry International

Volumn 50, Issue 1, 2007, Pages 119-129

  Setsuie, Rieko ^a,b   Wang, Yu Lai ^a   Mochizuki, Hideki ^c   Osaka, Hitoshi ^a,d   Hayakawa, Hideki ^c   Ichihara, Nobutsune ^e   Li, Hang ^a   Furuta, Akiko ^a   Sano, Yae ^a,b   Sun, Ying Jie ^a   Kwon, Jungkee ^a,f   Kabuta, Tomohiro ^a   Yoshimi, Kenji ^c   Aoki, Shunsuke ^a   Mizuno, Yoshikuni ^c   Noda, Mami ^b   Wada, Keiji ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^e AZABU UNIVERSITY   (Japan)

^f Chonbuk National University   (South Korea)

Author keywords

Animal model; Dopaminergic neuron; Parkinson's disease; Ubiquitin carboxy terminal hydrolase L1

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; PLATELET DERIVED GROWTH FACTOR B; UBIQUITIN THIOLESTERASE; UBIQUITIN THIOLESTERASE L1;

ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; IN VITRO STUDY; MESENCEPHALON; MOUSE; MUTANT; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PERIKARYON; PRIORITY JOURNAL; PROMOTER REGION; SILVER STAINING; SUBSTANTIA NIGRA; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; BASE SEQUENCE; DNA PRIMERS; DOPAMINE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; MUTATION; NEURONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

ANIMALIA; MUS MUSCULUS;

EID: 33845301143     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2006.07.015     Document Type: Article

References (50)

1. Aoki S., Su Q., Li H., Nishikawa K., Ayukawa K., Hara Y., Namikawa K., Kiryu-Seo S., Kiyama H., and Wada K. Identification of an axotomy-induced glycosylated protein, AIGP1, possibly involved in cell death triggered by endoplasmic reticulum-Golgi stress. J. Neurosci. 22 (2002) 10751-10760
2. Ardley H.C., Scott G.B., Rose S.A., Tan N.G., and Robinson P.A. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. J. Neurochem. 90 (2004) 379-391
3. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., and Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003) 256-259
4. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., and Destee A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364 (2004) 1167-1169
5. Chen L., Cagniard B., Mathews T., Jones S., Koh H.C., Ding Y., Carvey P.M., Ling Z., Kang U.J., and Zhuang X. Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J. Biol. Chem. 280 (2005) 21418-21426
6. Choi J., Levey A.I., Weintraub S.T., Rees H.D., Gearing M., Chin L.S., and Li L. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 279 (2004) 13256-13264
7. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
8. Farrer M., Kachergus J., Forno L., Lincoln S., Wang D.S., Hulihan M., Maraganore D., Gwinn-Hardy K., Wszolek Z., Dickson D., and Langston J.W. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55 (2004) 174-179
9. Fernagut P.O., and Chesselet M.F. Alpha-synuclein and transgenic mouse models. Neurobiol. Dis. 17 (2004) 123-130
10. Furuya T., Hayakawa H., Yamada M., Yoshimi K., Hisahara S., Miura M., Mizuno Y., and Mochizuki H. Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci. 24 (2004) 1865-1872
11. Goldberg M.S., Fleming S.M., Palacino J.J., Cepeda C., Lam H.A., Bhatnagar A., Meloni E.G., Wu N., Ackerson L.C., Klapstein G.J., Gajendiran M., Roth B.L., Chesselet M.F., Maidment N.T., Levine M.S., and Shen J. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278 (2003) 43628-43635
12. Goldberg M.S., Pisani A., Haburcak M., Vortherms T.A., Kitada T., Costa C., Tong Y., Martella G., Tscherter A., Martins A., Bernardi G., Roth B.L., Pothos E.N., Calabresi P., and Shen J. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45 (2005) 489-496
13. Hemelaar J., Borodovsky A., Kessler B.M., Reverter D., Cook J., Kolli N., Gan-Erdene T., Wilkinson K.D., Gill G., Lima C.D., Ploegh H.L., and Ovaa H. Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins. Mol. Cell. Biol. 24 (2004) 84-95
14. Hooper D., Kawamura M., Hoffman B., Kopin I.J., Hunyady B., Mezey E., and Eisenhofer G. Tyrosine hydroxylase assay for detection of low levels of enzyme activity in peripheral tissues. J. Chromatogr. B: Biomed. Sci. Appl. 694 (1997) 317-324
15. Ibanez P., Bonnet A.M., Debarges B., Lohmann E., Tison F., Pollak P., Agid Y., Durr A., and Brice A. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364 (2004) 1169-1171
16. Itier J.M., Ibanez P., Mena M.A., Abbas N., Cohen-Salmon C., Bohme G.A., Laville M., Pratt J., Corti O., Pradier L., Ret G., Joubert C., Periquet M., Araujo F., Negroni J., Casarejos M.J., Canals S., Solano R., Serrano A., Gallego E., Sanchez M., Denefle P., Benavides J., Tremp G., Rooney T.A., Brice A., and Garcia de Yebenes J. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet. 12 (2003) 2277-2291
17. Kahle P.J., Neumann M., Ozmen L., Muller V., Odoy S., Okamoto N., Jacobsen H., Iwatsubo T., Trojanowski J.Q., Takahashi H., Wakabayashi K., Bogdanovic N., Riederer P., Kretzschmar H.A., and Haass C. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am. J. Pathol. 159 (2001) 2215-2225
18. Kim R.H., Smith P.D., Aleyasin H., Hayley S., Mount M.P., Pownall S., Wakeham A., You-Ten A.J., Kalia S.K., Horne P., Westaway D., Lozano A.M., Anisman H., Park D.S., and Mak T.W. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 5215-5220
19. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
20. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 (1998) 106-108
21. Larsen C.N., Krantz B.A., and Wilkinson K.D. Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 37 (1998) 3358-3368
22. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., and Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature 395 (1998) 451-452
23. Lincoln S., Vaughan J., Wood N., Baker M., Adamson J., Gwinn-Hardy K., Lynch T., Hardy J., and Farrer M. Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. Neuroreport 10 (1999) 427-429
24. Liu Y., Fallon L., Lashuel H.A., Liu Z., and Lansbury Jr. P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111 (2002) 209-218
25. Lo Bianco C., Schneider B.L., Bauer M., Sajadi A., Brice A., Iwatsubo T., and Aebischer P. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 17510-17515
26. Lowe J., McDermott H., Landon M., Mayer R.J., and Wilkinson K.D. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J. Pathol. 161 (1990) 153-160
27. Maraganore D.M., Farrer M.J., Hardy J.A., Lincoln S.J., McDonnell S.K., and Rocca W.A. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 53 (1999) 1858-1860
28. Mochizuki H., Hayakawa H., Migita M., Shibata M., Tanaka R., Suzuki A., Shimo-Nakanishi Y., Urabe T., Yamada M., Tamayose K., Shimada T., Miura M., and Mizuno Y. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 10918-10923
29. Naito S., Mochizuki H., Yasuda T., Mizuno Y., Furusaka M., Ikeda S., Adachi T., Shimizu H.M., Suzuki J., Fujiwara S., Okada T., Nishikawa K., Aoki S., and Wada K. Characterization of multimetric variants of ubiquitin carboxyl-terminal hydrolase L1 in water by small-angle neutron scattering. Biochem. Biophys. Res. Commun. 339 (2006) 717-725
30. Naoi M., Takahashi T., and Nagatsu T. Simple assay procedure for tyrosine hydroxylase activity by high-performance liquid chromatography employing coulometric detection with minimal sample preparation. J. Chromatogr. 427 (1988) 229-238
31. Nishikawa K., Li H., Kawamura R., Osaka H., Wang Y.L., Hara Y., Hirokawa T., Manago Y., Amano T., Noda M., Aoki S., and Wada K. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem. Biophys. Res. Commun. 304 (2003) 176-183
32. Osaka H., Wang Y.L., Takada K., Takizawa S., Setsuie R., Li H., Sato Y., Nishikawa K., Sun Y.J., Sakurai M., Harada T., Hara Y., Kimura I., Chiba S., Namikawa K., Kiyama H., Noda M., Aoki S., and Wada K. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum. Mol. Genet. 12 (2003) 1945-1958
33. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., and Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
34. Palacino J.J., Sagi D., Goldberg M.S., Krauss S., Motz C., Wacker M., Klose J., and Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279 (2004) 18614-18622
35. Perez F.A., and Palmiter R.D. Parkin-deficient mice are not a robust model of parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 2174-2179
36. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
37. Rane N.S., Yonkovich J.L., and Hegde R.S. Protection from cytosolic prion protein toxicity by modulation of protein translocation. EMBO J. 23 (2004) 4550-4559
38. Saigoh K., Wang Y.L., Suh J.G., Yamanishi T., Sakai Y., Kiyosawa H., Harada T., Ichihara N., Wakana S., Kikuchi T., and Wada K. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet. 23 (1999) 47-51
39. Sandmann-Keil D., Braak H., Okochi M., Haass C., and Braak E. Alpha-synuclein immunoreactive Lewy bodies and Lewy neurites in Parkinson's disease are detectable by an advanced silver-staining technique. Acta Neuropathol. (Berl.) 98 (1999) 461-464
40. Sasahara M., Fries J.W., Raines E.W., Gown A.M., Westrum L.E., Frosch M.P., Bonthron D.T., Ross R., and Collins T. PDGF B-chain in neurons of the central nervous system, posterior pituitary, and in a transgenic model. Cell 64 (1991) 217-227
41. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., and Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
42. Uchihara T., Nakamura A., Mochizuki Y., Hayashi M., Orimo S., Isozaki E., and Mizutani T. Silver stainings distinguish Lewy bodies and glial cytoplasmic inclusions: comparison between Gallyas-Braak and Campbell-Switzer methods. Acta Neuropathol. (Berl.) 110 (2005) 255-260
43. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., and Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004) 1158-1160
44. Vila M., and Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat. Med. 10 Suppl. (2004) S58-S62
45. Von Coelln R., Thomas B., Savitt J.M., Lim K.L., Sasaki M., Hess E.J., Dawson V.L., and Dawson T.M. Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 10744-10749
46. Wang Y.L., Liu W., Sun Y.J., Kwon J., Setsuie R., Osaka H., Noda M., Aoki S., Yoshikawa Y., and Wada K. Overexpression of ubiquitin carboxyl-terminal hydrolase L1 arrests spermatogenesis in transgenic mice. Mol. Reprod. Develop. 73 (2006) 40-49
47. Wang Y.L., Takeda A., Osaka H., Hara Y., Furuta A., Setsuie R., Sun Y.J., Kwon J., Sato Y., Sakurai M., Noda M., Yoshikawa Y., and Wada K. Accumulation of beta- and gamma-synucleins in the ubiquitin carboxyl-terminal hydrolase L1-deficient gad mouse. Brain Res. 1019 (2004) 1-9
48. Watanabe I., Vachal E., and Tomita T. Dense core vesicles around the Lewy body in incidental Parkinson's disease: an electron microscopic study. Acta Neuropathol. (Berl.) 39 (1977) 173-175
49. Wilkinson K.D., Lee K.M., Deshpande S., Duerksen-Hughes P., Boss J.M., and Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246 (1989) 670-673
50. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Minsk B., Dickson D.W., Meeting T., Strom T.M., Wszolek Z.K., and Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with allomorphic pathology. Neurone 44 (2004) 601-607